Published in AIDS on April 24, 2015
Factors Associated With Plasma IL-6 Levels During HIV Infection. J Infect Dis (2015) 0.95
Role of immune activation in progression to AIDS. Curr Opin HIV AIDS (2016) 0.92
Initiation of antiretroviral therapy in early HIV infection reduces but does not abrogate chronic residual inflammation. Clin Infect Dis (2016) 0.91
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J Infect Dis (2016) 0.82
HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads. Front Microbiol (2015) 0.80
Immunological Signaling During Herpes Simplex Virus-2 and Cytomegalovirus Vaginal Shedding After Initiation of Antiretroviral Treatment. Open Forum Infect Dis (2016) 0.78
Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial. PLoS One (2016) 0.77
Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy. J Infect Dis (2016) 0.75
Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog (2017) 0.75
Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients. PLoS One (2015) 0.75
Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir. AIDS Res Hum Retroviruses (2016) 0.75
Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study. BMC Infect Dis (2017) 0.75
Frontline Science: c-Myc regulates P-selectin glycoprotein ligand-1 expression in monocytes during HIV-1 infection. J Leukoc Biol (2017) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Procedures for comparing samples with multiple endpoints. Biometrics (1984) 6.70
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis (2014) 3.66
Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis (2011) 3.25
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis (2014) 2.28
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood (2012) 2.03
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (2013) 1.71
HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS (2012) 1.55
Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest (2000) 1.38
Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis (1999) 1.34
The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine (2008) 1.16
Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol (2014) 1.13
A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol (2008) 1.06
Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep (2014) 1.01
Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01
CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals. J Immunol (2014) 0.96
Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. AIDS (2014) 0.84
Serum levels of cytokines and chemokines associated with cardiovascular disease in Brazilian patients treated with statins for dyslipidemia. Int Immunopharmacol (2013) 0.80
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol (2002) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS (2006) 2.77
Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ (2012) 2.66
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. Crit Care Med (2015) 2.62
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS (2011) 2.45
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis (2010) 2.37
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr (2003) 2.33
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis (2010) 2.32
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health (2010) 2.21
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17
Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res (2004) 2.17
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS (2002) 2.02
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99
Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr (2002) 1.97
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis (2009) 1.95
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood (2012) 1.91
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood (2002) 1.70
Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis (2009) 1.66
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS (2002) 1.63
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr (2002) 1.59
Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 1.58
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J Infect Dis (2004) 1.55
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res (2011) 1.51
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect (2010) 1.49
Achieving compliance with the European Working Time Directive in a large teaching hospital: a strategic approach. Clin Med (2004) 1.49
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS (2007) 1.48
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
The changing pattern of bronchoscopy in an HIV-infected population. Chest (2002) 1.42
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis (2007) 1.42
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol (2007) 1.41
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Iatrogenic effects of group treatment for antisocial youths. J Consult Clin Psychol (2005) 1.41
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS (2003) 1.41
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS (2004) 1.40
Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect (2010) 1.40
Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One (2014) 1.35
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis (2006) 1.32
Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis (2006) 1.31
Suicidal ideation in UK HIV clinic attenders. AIDS (2008) 1.31
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther (2011) 1.30
CD4 immunophenotyping in HIV infection. Nat Rev Microbiol (2008) 1.27
Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS (2009) 1.26
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis (2012) 1.25
Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS (2008) 1.23
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther (2008) 1.21
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis (2004) 1.21
Impact of a cell phone intervention on mediating mechanisms of smoking cessation in individuals living with HIV/AIDS. Nicotine Tob Res (2006) 1.21
Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.20
Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS (2010) 1.17
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther (2007) 1.17
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17
Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One (2012) 1.16
Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load. J Clin Microbiol (2009) 1.15
Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest (2014) 1.14
Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr (2002) 1.14
Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature (2006) 1.13